(R)-1-[3-(三氟甲基)苯基]乙胺 | 127852-30-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-1-[3-(三氟甲基)苯基]乙胺
• 中文别名: (R)-1-[3-(三氟甲基)苯基]乙胺盐酸盐
• 英文名称: (1R)-1-[3-(trifluoromethyl)phenyl]ethanamine
• 英文别名: (1R)-1-[3-(trifluoromethyl)phenyl]ethylamine；(1R)-1-[3-(trifluoromethyl)phenyl]ethan-1-amine；(R)-1-(3-(trifluoromethyl)phenyl)ethan-1-amine；(R)-{1-[3-(trifluoromethyl)phenyl]ethyl}amine；(R)-1-(3-(trifluoromethyl)phenyl)ethanamine
• CAS: 127852-30-6
• 化学式: C₉H₁₀F₃N
• mdl: MFCD03093005
• 分子量: 189.18
• InChiKey: ODZXRBRYQGYVJY-ZCFIWIBFSA-N

物化性质

• 沸点：
  184.1±35.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P305+P351+P338
• 危险品运输编号：
  2735
• 危险性描述：
  H302,H318
• 储存条件：
  惰性气体，存储温度：2-8℃

反应信息

• 作为反应物：
  描述：

  (R)-1-[3-(三氟甲基)苯基]乙胺 在 palladium on activated charcoal N-羟基-7-氮杂苯并三氮唑 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 Butanoic acid,3-amino-4-oxo-4-[[(1R)-1-[3-(trifluoromethyl)phenyl]ethyl]amino]-,1,1-dimethylethyl ester, (3R)-
  参考文献：
  名称：

  Azetidinones as vasopressin V1a antagonists

  摘要：

  The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing hormone receptor. Structure-activity relationships for the series were explored to optimize receptor affinity and pharmacokinetic properties, resulting in compounds with K-i values < 1 nM and brain levels after oral dosing similar to 100-fold higher than receptor affinities.[GRAPHICS](c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.12.031
• 作为产物：
  描述：

  1-(3-三氟甲基苯基)乙醇 在 2,2,6,6-四甲基哌啶氧化物 、 Trametes versicolor laccase 、 磷酸吡哆醛 、 transaminase ATA-013 、 异丙胺 作用下， 以 aq. phosphate buffer 、 甲基叔丁基醚 、 二甲基亚砜 为溶剂， 反应 40.0h， 生成 (R)-1-[3-(三氟甲基)苯基]乙胺
  参考文献：
  名称：

  Stereoselective amination of racemic sec-alcohols through sequential application of laccases and transaminases

  摘要：

  已开发出一种一锅法/两步法的化学酶串联方法，通过将来自Trametes versicolor的漆酶/TEMPO催化系统与转氨酶的立体选择性作用相结合，实现了对次级醇的选择性胺化。

  DOI：

  10.1039/c6gc01981a

文献信息

• BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Revolution Medicines, Inc.

  公开号：US20210139517A1

  公开（公告）日：2021-05-13

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
• [EN] NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS<br/>[FR] NOUVELLES QUINAZOLINES À SUBSTITUTION BENZYLAMINO ET LEURS DÉRIVÉS EN TANT QU'INHIBITEURS DE SOS1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018115380A1

  公开（公告）日：2018-06-28

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.

  本发明涵盖了式（I）的化合物，其中基团R1至R7具有权利要求和说明中给定的含义，它们作为SOS1的抑制剂的用途，包含这种化合物的药物组合物以及它们作为药物/医疗用途的用途，特别是作为治疗和/或预防肿瘤疾病的药剂。
• [EN] SUBSTITUTED TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS
  申请人：LUPIN LTD

  公开号：WO2021130731A1

  公开（公告）日：2021-07-01

  Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

  本文披露了一般式（I）的化合物，其互变异构体，立体异构体，药用可接受的盐，其多晶形或溶剂化合物，其中，环A，环B，R1至R4和n如本处定义，用作SOS1抑制剂，用于治疗增生性、感染性和RAS病或障碍。还披露了一种合成一般式I化合物的方法，含有一般式I化合物的制药组合物，治疗增生性、感染性和RAS病或障碍的方法，例如，癌症，通过给予所述化合物和一般式I化合物与其他活性成分的组合。
• [EN] BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE BICYCLIQUES ET LEURS UTILISATIONS
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2020180768A1

  公开（公告）日：2020-09-10

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
• Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same
  申请人：Central Glass Company, Limited

  公开号：US06797842B2

  公开（公告）日：2004-09-28

  An optically active 1-(fluoro- or trifluoromethyl-substituted phenyl)ethylamine is produced with high optical purity and in an industrially simple and efficient manner by asymmetrically reducing an optically active imine, obtained by dehydration and condensation of a fluoro- or trifluoromethyl-substituted phenylmethyl ketone and an optically active primary amine under acidic conditions, using a hydride reducing agent to convert to an optically active secondary amine, and subjecting the secondary amine or its salt of an inorganic acid or organic acid to hydrogenolysis. In addition, an optically active 1-(fluoro- or trifluoromethyl-substituted phenyl)ethylamine is purified to an even higher optical purity in an industrially simple and efficient manner by converting the optically active secondary amine of the synthetic intermediate obtained by asymmetric reduction, or an optically active 1-(3,5-bis-trifluoromethylphenyl)ethylamine, one of the target compounds, to an inorganic or organic acid salt followed by recrystallization purification. This ethylamine is an important intermediate of pharmaceuticals and agricultural chemicals.

  通过在酸性条件下将氟代或三氟甲基取代的苯甲基酮和光学活性的初级胺脱水和缩合得到的光学活性亚胺，再使用氢化还原剂将其转化为光学活性的二级胺，然后将这个二级胺或其无机酸或有机酸盐进行氢解，可以以高光学纯度和在工业上简单高效的方式生产光学活性的1-(氟代或三氟甲基取代的苯基)乙胺。此外，通过将通过不对称还原得到的合成中间体的光学活性二级胺，或目标化合物之一的光学活性1-(3,5-双三氟甲基苯基)乙胺转化为无机或有机酸盐，然后进行重结晶纯化，可以以工业上简单高效的方式将光学活性的1-(氟代或三氟甲基取代的苯基)乙胺提纯至更高的光学纯度。这种乙胺是制药和农药化学品的重要中间体。